Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity andKRASstatus in patients receiving panitumumab monotherapy-Reference-Cited by-同舟云学术

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity andKRASstatus in patients receiving panitumumab monotherapy

Published:2009-04-01 Issue:7 Volume:115 Page:1544-1554
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Peeters Marc,Siena Salvatore,Van Cutsem Eric,Sobrero Alberto,Hendlisz Alain,Cascinu Stefano,Kalofonos Haralabos,Devercelli Giovanna,Wolf Michael,Amado Rafael G.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference29 articles.

1. Global cancer statistics, 2002;Parkin;CA Cancer J Clin.,2005

2. Open-label, phase 3 clinical trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer;Van Cutsem;J Clin Oncol.,2007

3. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer;Cunningham;N Engl J Med.,2004

4. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor;Saltz;J Clin Oncol.,2004

5. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med.,2004

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Facial Papulopustular Eruption during the COVID-19 Pandemic in Patients Treated with EGFR Inhibitors;Dermatology Research and Practice;2024-01-11

2. Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study;JTO Clinical and Research Reports;2023-12

3. A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries;British Journal of Dermatology;2023-03-27

4. Guarantee‐time bias in studies on the relationship between immune‐related adverse events and antitumor activity;Cancer;2022-04-22

5. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?;Supportive Care in Cancer;2021-11-15